(Q36383766)

13 August 2017

1 reference

title

Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management (English)

1 reference

13 August 2017

0 references

1 reference

1 reference

Jennifer M Loftis

1

1 reference

13 August 2017

Annette M Matthews

series ordinal

2

1 reference

13 August 2017

Peter Hauser

series ordinal

3

1 reference

13 August 2017

language of work or name

1 reference

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

66

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

155-174

1 reference

An Inventory for Measuring Depression

13 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666020-00003

Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.

21 January 2018

1 reference

12 December 2020

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

1 reference

12 December 2020

Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin

1 reference

12 December 2020

Update on viral hepatitis in 2004.

1 reference

12 December 2020

Treating hepatitis C in methadone maintenance patients: an interim analysis

1 reference

12 December 2020

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

1 reference

12 December 2020

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

12 December 2020

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

1 reference

12 December 2020

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

12 December 2020

Treatment of hepatitis C infection in injection drug users

1 reference

12 December 2020

Meta-analysis of serotonin transporter polymorphisms and affective disorders

1 reference

12 December 2020

Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?

1 reference

12 December 2020

Diagnosis, management, and treatment of hepatitis C

1 reference

12 December 2020

Prophylactic treatment of depression induced by interferon-alpha

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

12 December 2020

Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275.

1 reference

12 December 2020

Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease

1 reference

12 December 2020

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

1 reference

12 December 2020

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

12 December 2020

Response to interferon alpha therapy is influenced by the iron content of the liver

1 reference

12 December 2020

The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test

1 reference

12 December 2020

The alcoholic patient with hepatitis C virus infection

1 reference

12 December 2020

Interferon-induced mania

1 reference

12 December 2020

Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients

1 reference

12 December 2020

Inter- and Intra-Rater Reliability of the Brief Psychiatric Rating Scale

1 reference

12 December 2020

Is the management of hepatitis C patients appropriate? A population-based study.

1 reference

12 December 2020

Mechanisms of type-I- and type-II-interferon-mediated signalling

1 reference

12 December 2020

Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.

1 reference

12 December 2020

The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings

1 reference

12 December 2020

Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database.

1 reference

12 December 2020

The phenomenology and treatment of interferon-induced depression.

1 reference

12 December 2020

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

12 December 2020

Alcohol use and hepatitis C.

1 reference

12 December 2020

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection

1 reference

12 December 2020

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

1 reference

12 December 2020

The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes

1 reference

12 December 2020

Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use.

1 reference

12 December 2020

Monitoring depression in patients undergoing alpha-interferon and ribavirin therapy for hepatitis C.

1 reference

12 December 2020

Adherence to combination therapy: influence on sustained virologic response and economic impact

1 reference

12 December 2020

A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS)

1 reference

12 December 2020

Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease

1 reference

12 December 2020

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

12 December 2020

Treatment prediction in depression using a self-rating scale

1 reference

12 December 2020

Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus

1 reference

12 December 2020

Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C.

1 reference

12 December 2020

Side effects of therapy of hepatitis C and their management

1 reference

12 December 2020

Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin

1 reference

12 December 2020

Cohort effect of HCV infection in liver cirrhosis assessed by a 25 year study.

1 reference

12 December 2020

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

1 reference

12 December 2020

A rating scale for mania: reliability, validity and sensitivity

1 reference

12 December 2020

Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature

1 reference

12 December 2020

Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes.

1 reference

12 December 2020

Persistent BBB disruption may underlie alpha interferon-induced seizures

1 reference

12 December 2020

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

12 December 2020

Treating hepatitis C virus infection in active substance users

1 reference

12 December 2020

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

12 December 2020

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions

1 reference

12 December 2020

Sertraline treatment of interferon-alfa-induced depressive disorder

1 reference

12 December 2020

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

12 December 2020

Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C.

1 reference

12 December 2020

Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness.

1 reference

12 December 2020

Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.

1 reference

12 December 2020

Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C

1 reference

12 December 2020

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

12 December 2020

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

12 December 2020

Psychiatric disorders among veterans with hepatitis C infection

1 reference

12 December 2020

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

1 reference

12 December 2020

An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.

1 reference

12 December 2020

Public health and hepatitis C.

1 reference

12 December 2020

Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin

1 reference

12 December 2020

Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU) : guidelines for clinical practice

1 reference

12 December 2020

Treatment for amphetamine psychosis.

1 reference

12 December 2020

Treatment of hepatitis C viral infections in substance abusers.

1 reference

12 December 2020

Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma.

1 reference

12 December 2020

Hepatitis C and human immunodeficiency virus infection

1 reference

12 December 2020

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

12 December 2020

A Case Report of Naltrexone for Alcoholism in a Liver Transplant Recipient: Side Effects and Safety

1 reference

12 December 2020

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.

1 reference

12 December 2020

Depression from interferon therapy in patients with hepatitis C

1 reference

12 December 2020

Emotional distress in chronic hepatitis C patients not receiving antiviral therapy.

1 reference

12 December 2020

Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.

1 reference

12 December 2020

Hepatocellular carcinoma: the need for progress.

1 reference

12 December 2020

Treatment of chronic hepatitis C in active drug users.

1 reference

12 December 2020

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up

1 reference

12 December 2020

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

1 reference

12 December 2020

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

1 reference

12 December 2020

Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population

1 reference

12 December 2020

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

12 December 2020

A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance

1 reference

12 December 2020

Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy

1 reference

12 December 2020

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

1 reference

12 December 2020

Clinical course of hepatitis C virus during the first decade of infection: cohort study

1 reference

12 December 2020

Hepatitis C among noninjecting drug users: a report

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

12 December 2020

The Alcohol Abstinence Self-Efficacy scale

1 reference

12 December 2020

Former addicts face barriers to treatment for HCV

1 reference

12 December 2020

Rheumatic manifestations of hepatitis C infection

1 reference

12 December 2020

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users

1 reference

12 December 2020

Bipolar disorder, antidepressants and induction of hypomania or mania. A systematic review

1 reference

12 December 2020

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

12 December 2020

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

1 reference

12 December 2020

Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

1 reference

12 December 2020

Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects

1 reference

12 December 2020

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

12 December 2020

Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.

1 reference

12 December 2020

HIV and HCV infection among injecting drug users.

1 reference

12 December 2020

Disulfiram use in patients with abnormal liver function test results

1 reference

12 December 2020

Disulfiram therapy in patients with hepatitis C: a 12-month, controlled, follow-up study

1 reference

12 December 2020

Liver disease in alcohol and hepatitis C.

1 reference

12 December 2020

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

1 reference

12 December 2020

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

12 December 2020

Clinical significance of hepatitis C virus genotypes.

1 reference

12 December 2020

Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

1 reference

12 December 2020

Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis.

1 reference

12 December 2020

Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score

1 reference

12 December 2020

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

1 reference

12 December 2020

Alcohol and hepatitis C

1 reference

12 December 2020

Seizures during alpha interferon therapy

1 reference

12 December 2020

Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis

1 reference

12 December 2020

Fluoxetine treatment of depression caused by interferon-alpha.

1 reference

12 December 2020

Seizures associated with low-dose alpha-interferon

1 reference

12 December 2020

Liver diseases by alcohol and hepatitis C: early detection and new insights in pathogenesis lead to improved treatment

1 reference

12 December 2020

The treatment of chronic viral hepatitis

1 reference

12 December 2020

Limited success of HCV antiviral therapy in United States veterans

1 reference

12 December 2020

Hepatitis C virus-infected patients report communication problems with physicians

1 reference

12 December 2020

Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: results of a pilot study.

1 reference

12 December 2020

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

12 December 2020

Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.

1 reference

12 December 2020

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

12 December 2020

Prevalence of hepatitis B and hepatitis C markers in alcoholics with and without clinically evident hepatic cirrhosis

1 reference

12 December 2020

Mood and cognitive side effects of interferon-alpha therapy

1 reference

12 December 2020

Alcohol, hepatotropic viruses, and hepatocellular carcinoma.

1 reference

12 December 2020

[Psychiatric complications of interferon therapy]

1 reference

12 December 2020

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression

1 reference

12 December 2020

Hepatitis C in alcohol dependence:drinking versus disulfiram

1 reference

12 December 2020

Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.

1 reference

12 December 2020

10.2165/00003495-200666020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1017666065

0 references

1 reference